UBS initiated coverage on Zai Lab Limited (NASDAQ:ZLAB) with a Buy rating and $35 price target. The research firm sees the company as undervalued and highlighted its global pipeline potential. Zai Lab also received approval for its drug AUGTYRO in China for patients with certain tumors. The company focuses on therapies for unmet medical needs.

Read more at Yahoo Finance: UBS Gives Zai Lab (ZLAB) a Buy Rating